4th Annual Tumor Models Boston 2016
Science has seen many great partnerships over the years, and we think one of the current top match ups is Hanson Wade’s Tumor Models Conference and CrownBio. The Tumor Models events (held annually in both Boston and London) share the best preclinical research, aiming to enhance predictability and translational success for the next generation of targeted cancer therapies, which perfectly matches our preclinical oncology aims.
The conferences allow not only presentation of cutting edge work, but also round table discussion and dedicated networking time to encourage the most engaging collaboration and debate.
The 4th Annual Tumor Models Boston event saw CrownBio again acting as lead partner, with an experienced research and BD team in attendance, including Dr Eric Murphy Global Head Oncology R&D Strategy and External Innovations and Dr Tommy Broudy, General Manager, CrownBio San Diego.
Eric kicked off proceedings on Day 1 with a presentation on CrownBio’s Global Immuno-Oncology Platform covering our triple arm of immunotherapy platforms of murine, human, and chimeric immunity. Our data on:
- humanized patient-derived xenograft (PDX) studies
- MuScreen™ (our large scale syngeneic screening platform)
- and HuGEMM™ - CrownBio’s unique chimeric platform featuring humanized drug targets within a fully functional murine immune system for evaluation of human-specific immuno-oncology therapeutics
were a well received and very apt start to the meeting, which focused heavily on immunotherapy.
Eric and Tommy reported back enthusiastically on the main highlights from the 2 day event, including general attendee debate, presentations, and round table discussions:
- “Humanized mice (which we use for our HSC-PDX studies) were, as expected, a hot topic for many attendees who were most interested in discussing the advantages of NSG™ from The Jackson Laboratory versus NSG-SGM3 models which offer improved Teff, Treg, and monocyte/macrophage engraftment rates, as well as improved CD4 and CD8 engraftment for checkpoint and co-stimulatory receptor studies. Rick Huntress from The Jackson Lab gave an update on these new models which feature the addition of three human cytokines (GM-CSF, IL-3, and Kit ligand) into the NSG mouse to provide a more robust myeloid compartment after humanization.
- The roundtable discussion chaired by David Deems, President of Cellaria Bioscience discussed problems with mimicking the patient microenvironment in advanced 3D culture and PDX with murine stroma replacement, with engaging ideas on how to improve patient-specific models to inform clinical treatment strategies.
- Immuno-oncology combination treatment was also a dominant theme, including immunogenic cell death (ICD) inducers (anthracyclines in combination with checkpoint mAbs) and ADC immuno-conjugates”.
The conference also provided the opportunity for deeper access into attendee’s innovative research, with a poster session, allowing the chance for scientist’s brains to be picked on their current work. We presented more details on MuScreen, our large scale, in vivo, staggered syngeneic screening platform for immuno-oncology agents allowing further discussion following on from Eric’s earlier talk.
The tumor models event allowed the chance for fertile discussions on the future of immuno-oncology, and preclinical models such as PDX, from the researchers and companies at the forefront of these fields. CrownBio’s take home message was that the pursuit of improved in vivo models for immunotherapy will continue to be a trend for quite some time, with the expansion of NSG-SGM3 use likely, and improved understanding of host response in humanized models also greatly needed to advance the immunotherapy field.